Article

Retinocytoma characterized by four characteristic features

Retinocytoma is a rare benign tumor with characteristic clinical features. Arun Singh, MD, director, Department of Ophthalmic Oncology, Cole Eye Institute, Cleveland, OH, United States, described how to differentiate this retinal pathology from other pathologies.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game? (Part 1)
(Image credit: Ophthalmology Times) From MIGS to gene therapy: Inder Paul Singh, MD, celebrates the past and future of glaucoma care
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
Related Content
PulseSight doses first patient in PST-611-CT1
July 9th 2025

PulseSight doses first patient in PST-611-CT1

3 Things You Should Know About the GA Pipeline
June 4th 2025

3 Things You Should Know About Interventional Glaucoma Comanagement

Health Canada approves aflibercept biosimilar Aflivu
July 8th 2025

Health Canada approves aflibercept biosimilar Aflivu

Patient-Centered Treatment Strategies in the Management of nAMD and DME
May 30th 2025

Patient-Centered Treatment Strategies in the Management of nAMD and DME

A look at the vorolanib intravitreal insert compared with aflibercept for DME
July 8th 2025

A look at the vorolanib intravitreal insert compared with aflibercept for DME

Boehringer Ingelheim launches phase 2 study of oral therapy for diabetic macular edema
July 8th 2025

Boehringer Ingelheim launches phase 2 study of oral therapy for diabetic macular edema

© 2025 MJH Life Sciences

All rights reserved.